T
TravisB
Guest
You mean on "they won't tell us too much"?
dimitar_berbagod said:Agree completely with Northman and Nilli. People are far too quick to jump to conclusions. I know its all doom and gloom at the moment but this certainly doesn't mean they've failed. Nor will they announce a cure. Regardless of the retraction of their statement, the best we'd have got from phase 1 is 'no patients reported adverse affects...the product is safe etc'.
Incidentally, I found this on another forum... make of it what you will...
Hi everyone, I just wanted to say that I called the communication department of replicel just before it's closing time on Friday.
I asked them if the "retraction of public disclosure" was related to the results
of the trial at all.
I was assured the the retraction had nothing to do at all with the trial results.
I was told that some stock promoters wrote things that were not approved by replicel. They just wanted to protect themselves legally.
I believe lawsuits in the U.S. are very common when companies take a large downward spiral for whatever reason. knowing the risking business that replicel is in, it was probably a good idea to try and protect themselves as much as possible from any potential future lawsuits.
The communication person did not see the results and did not know results of the trail.
I still think that since replicel waited untill Monday to announce the results instead of Friday is a good sign though.
monty1978 said:TravisB said:You mean on "they won't tell us too much"?
That's right!
VANCOUVER, BC – April 3, 2012 – RepliCel Life Sciences Inc. (the “Company†or “RepliCelâ€) (OTCBB: REPCF) is pleased to report that all 19 subjects have completed their six-month post injection follow-up visit and the company remains on schedule to release the initial review of efficacy results in April 2012. The data collected from the first six months following injection will be used for assessment of the primary safety and secondary safety and efficacy endpoints for the TS001-2009 clinical trial.
...
Subject efficacy at 6-months post injection is the first step in measuring a treatment response. All subjects will continue to participate in the post injection follow-up period of the study until August 2013 and a review of final safety and efficacy results will commence before the end of 2013. The continued follow-up period is a key component of the study to confirm treatment safety profile and response trends at 6, 12 and 24 months
TravisB said:^ what forum exactly?
Now someone else on BTT wrote that the interview will be followed with official news release.
I don't have an account there so I can't ask where they are getting this info from, and if they aren't shitting.
Replicel Life Sciences spoke with Spencer Kobren this morning to provide an update. According to a company spokesperson, the complete analysis of their collected data is still in the process of being completed for release and the company will be making their official announcement within the next few days. There will be no announcement concerning their current results today, however, Spencer Kobren will be interviewing Replicel's CEO David Hall as soon soon as their announcement is made.